[go: up one dir, main page]

EA201991345A1 - Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip - Google Patents

Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip

Info

Publication number
EA201991345A1
EA201991345A1 EA201991345A EA201991345A EA201991345A1 EA 201991345 A1 EA201991345 A1 EA 201991345A1 EA 201991345 A EA201991345 A EA 201991345A EA 201991345 A EA201991345 A EA 201991345A EA 201991345 A1 EA201991345 A1 EA 201991345A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glucagon
glp1
receptor agonists
new compounds
gip receptor
Prior art date
Application number
EA201991345A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991345A1 publication Critical patent/EA201991345A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к тройным агонистам рецепторов GLP-1/глюкагона/GIP и их медицинскому применению, например, в лечении нарушений при метаболическом синдроме, в том числе диабета и ожирения, а также для снижения избыточного потребления пищи.
EA201991345A 2016-12-02 2017-12-01 Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip EA201991345A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306604 2016-12-02
PCT/EP2017/081125 WO2018100134A1 (en) 2016-12-02 2017-12-01 New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists

Publications (1)

Publication Number Publication Date
EA201991345A1 true EA201991345A1 (ru) 2019-11-29

Family

ID=57542935

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991345A EA201991345A1 (ru) 2016-12-02 2017-12-01 Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip

Country Status (23)

Country Link
US (1) US10538567B2 (ru)
EP (1) EP3548508B1 (ru)
JP (1) JP7100033B2 (ru)
KR (1) KR102576872B1 (ru)
CN (1) CN110023329B (ru)
AR (1) AR110300A1 (ru)
AU (1) AU2017367173B2 (ru)
BR (1) BR112019011228A2 (ru)
CA (1) CA3045377A1 (ru)
CL (1) CL2019001465A1 (ru)
CO (1) CO2019006917A2 (ru)
CR (1) CR20190313A (ru)
DO (1) DOP2019000068A (ru)
EA (1) EA201991345A1 (ru)
EC (1) ECSP19046893A (ru)
IL (1) IL266984A (ru)
MA (1) MA46955A (ru)
MX (1) MX2019006429A (ru)
PE (1) PE20191143A1 (ru)
PH (1) PH12019501216A1 (ru)
TW (1) TW201833132A (ru)
UY (1) UY37506A (ru)
WO (1) WO2018100134A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
EP3774838B1 (en) 2018-04-10 2022-08-10 Sanofi-Aventis Deutschland GmbH Lixisenatide synthesis with capping
US11560402B2 (en) 2018-04-10 2023-01-24 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
UY38249A (es) 2018-05-30 2019-12-31 Sanofi Sa Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico
WO2020130749A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
EP4043026A4 (en) * 2019-10-04 2024-01-10 Hanmi Pharm. Co., Ltd. Glucagon, composition comprising glp-1 receptor and gip receptor dual agonist and therapeutic use thereof
CA3156452A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
TW202140058A (zh) * 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
CN116171282A (zh) 2020-08-07 2023-05-26 勃林格殷格翰国际有限公司 可溶npy2受体激动剂
WO2022035302A1 (ko) * 2020-08-14 2022-02-17 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물
CN112409460B (zh) * 2020-11-27 2022-02-01 江苏师范大学 一类glp-1/胰高血糖素受体双重激动剂及其应用
CN116669752A (zh) * 2020-12-16 2023-08-29 西兰制药公司 Glp-1/glp-2双重激动剂的药物组合物
TW202228764A (zh) * 2020-12-16 2022-08-01 丹麥商西蘭製藥公司 Ｇｌｐ－１／ｇｌｐ－２雙重促效劑之醫藥組合物
CA3223121A1 (en) * 2021-06-25 2022-12-29 Eli Lilly And Company Methods for treating obstructive sleep apnea
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
EP4532530A1 (en) * 2022-05-27 2025-04-09 D&D Pharmatech Inc. Peptide compositions and methods of use threof
WO2024067662A1 (zh) * 2022-09-28 2024-04-04 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途
WO2025049610A1 (en) * 2023-08-28 2025-03-06 Shattuck Labs, Inc. Multi-action peptides
CN117586374B (zh) * 2023-10-07 2024-11-29 深圳湾实验室 Glp-1r/gipr/gcgr三重激动剂类似物及其用途
CN119241684B (zh) * 2024-11-22 2025-02-25 徐州医科大学 一种肠促胰岛素类似物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500295A1 (en) 2002-10-02 2004-04-29 Zealand Pharma A/S Stabilized exendin-4 compounds
US20080019911A1 (en) * 2005-04-20 2008-01-24 Aimin Xu Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
EA020326B9 (ru) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
ES2713952T3 (es) 2010-12-22 2019-05-24 Univ Indiana Res & Tech Corp Análogos de glucagón que muestran actividad de receptor de GIP
AR091478A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa)
WO2013192129A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211231A1 (en) * 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080151A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物

Also Published As

Publication number Publication date
US10538567B2 (en) 2020-01-21
PE20191143A1 (es) 2019-09-02
CN110023329A (zh) 2019-07-16
CL2019001465A1 (es) 2019-10-18
MX2019006429A (es) 2019-08-21
UY37506A (es) 2018-06-29
EP3548508A1 (en) 2019-10-09
PH12019501216A1 (en) 2019-08-19
CR20190313A (es) 2019-09-11
AU2017367173A1 (en) 2019-07-18
AR110300A1 (es) 2019-03-13
JP2019536796A (ja) 2019-12-19
WO2018100134A1 (en) 2018-06-07
DOP2019000068A (es) 2019-05-31
JP7100033B2 (ja) 2022-07-12
BR112019011228A2 (pt) 2019-10-15
CO2019006917A2 (es) 2019-07-10
TW201833132A (zh) 2018-09-16
EP3548508B1 (en) 2021-10-27
US20180155406A1 (en) 2018-06-07
MA46955A (fr) 2021-05-19
CA3045377A1 (en) 2018-06-07
KR102576872B1 (ko) 2023-09-12
KR20190085141A (ko) 2019-07-17
CN110023329B (zh) 2024-05-03
IL266984A (en) 2019-07-31
AU2017367173B2 (en) 2022-03-24
ECSP19046893A (es) 2019-07-31

Similar Documents

Publication Publication Date Title
EA201991345A1 (ru) Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
EA201590715A1 (ru) Производные эксендина-4 как двойные агонисты glp1/глюкагона
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
EA201690606A1 (ru) Аналоги глюкагона
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
EA202091290A1 (ru) Аналоги инкретина и их применение
EA201690660A1 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
EA202090392A3 (ru) Соединения-коагонисты гип и гпп-1
MX2015008079A (es) Agonista duales de glp1/gip o trigonales de glp1/gip/glucagon.
EA202091284A1 (ru) Аналоги инкретина и их применение
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
EA201590011A1 (ru) Пептидные аналоги эксендина-4
EA201590294A1 (ru) Аналоги глюкагона
CR20180378A (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
EA201591839A1 (ru) Терапевтические пептиды
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств